Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

Opinion
Video

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
      Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
      Future of HER2-Directed Tumor-Agnostic Therapies
      Future of HER2-Directed Tumor-Agnostic Therapies
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      HER2 Key Differences and Current Approaches to Biomarker Testing
      HER2 Key Differences and Current Approaches to Biomarker Testing
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
      Lung Cancer Home Health Screening Tools May Aid in Triaging LDCT+ Patients
      An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
      Cell-Free DNA Assay Achieves High Negative Predicative Value in Lung Cancer
      Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
      Blood Testing for Lung Cancer May Address Inadequate Screening Utilization
      Related Content
      HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

      HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

      Tim Cortese
      May 6th 2025
      Article

      A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.

      Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

      Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

      Georgios Evangelou, MD, MSc
      September 16th 2024
      Podcast

      Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

      Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

      Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

      Tim Cortese
      April 27th 2025
      Article

      Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.

      Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

      Achieving Health Equity in Lung Cancer Surgery

      Rian M. Hasson Charles, MD, MPH, FACS
      April 1st 2024
      Podcast

      Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

      A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

      Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

      Russ Conroy
      April 23rd 2025
      Article

      A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

      “These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).

      TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

      Russ Conroy
      April 23rd 2025
      Article

      Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.